JP2017518318A5 - - Google Patents

Info

Publication number

JP2017518318A5

JP2017518318A5 JP2016571256A JP2016571256A JP2017518318A5 JP 2017518318 A5 JP2017518318 A5 JP 2017518318A5 JP 2016571256 A JP2016571256 A JP 2016571256A JP 2016571256 A JP2016571256 A JP 2016571256A JP 2017518318 A5 JP2017518318 A5 JP 2017518318A5

Authority

JP

Japan

Prior art keywords

fragment

seq

sequence

antibody

composition

Prior art date

2015-06-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims description 78
• 239000000203 mixture Substances 0.000 claims description 32
• 150000001413 amino acids Chemical class 0.000 claims description 22
• 150000003904 phospholipids Chemical class 0.000 claims description 18
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
• 102000004148 Annexin A4 Human genes 0.000 claims description 14
• 108090000669 Annexin A4 Proteins 0.000 claims description 14
• 229920001184 polypeptide Polymers 0.000 claims description 14
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
• 201000010099 disease Diseases 0.000 claims description 9
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 8
• 230000000295 complement effect Effects 0.000 claims description 8
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 8
• 230000001404 mediated effect Effects 0.000 claims description 8
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 8
• 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 8
• WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 6
• 229940118019 malondialdehyde Drugs 0.000 claims description 6
• 230000008685 targeting Effects 0.000 claims description 6
• 208000037816 tissue injury Diseases 0.000 claims description 6
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
• 108020001507 fusion proteins Proteins 0.000 claims description 4
• 102000037865 fusion proteins Human genes 0.000 claims description 4
• 241000701161 unidentified adenovirus Species 0.000 claims description 4
• 230000004792 oxidative damage Effects 0.000 claims description 3
• 239000008194 pharmaceutical composition Substances 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 241000702421 Dependoparvovirus Species 0.000 claims description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
• 206010003246 arthritis Diseases 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 102000039446 nucleic acids Human genes 0.000 claims description 2
• 108020004707 nucleic acids Proteins 0.000 claims description 2
• 150000007523 nucleic acids Chemical class 0.000 claims description 2
• 239000013612 plasmid Substances 0.000 claims description 2
• 241001430294 unidentified retrovirus Species 0.000 claims description 2
• 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
• 208000026872 Addison Disease Diseases 0.000 claims 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
• 208000023328 Basedow disease Diseases 0.000 claims 1
• 208000011231 Crohn disease Diseases 0.000 claims 1
• 206010018364 Glomerulonephritis Diseases 0.000 claims 1
• 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
• 208000015023 Graves' disease Diseases 0.000 claims 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
• 208000001204 Hashimoto Disease Diseases 0.000 claims 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
• 208000005777 Lupus Nephritis Diseases 0.000 claims 1
• 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
• 241000721454 Pemphigus Species 0.000 claims 1
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
• 206010037549 Purpura Diseases 0.000 claims 1
• 241001672981 Purpura Species 0.000 claims 1
• 208000033626 Renal failure acute Diseases 0.000 claims 1
• 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
• 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
• 208000027418 Wounds and injury Diseases 0.000 claims 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 1
• 201000011040 acute kidney failure Diseases 0.000 claims 1
• 206010064930 age-related macular degeneration Diseases 0.000 claims 1
• 201000004995 autoimmune glomerulonephritis Diseases 0.000 claims 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
• 208000020832 chronic kidney disease Diseases 0.000 claims 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
• 230000006378 damage Effects 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
• 208000014674 injury Diseases 0.000 claims 1
• 208000002780 macular degeneration Diseases 0.000 claims 1
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
• 210000002784 stomach Anatomy 0.000 claims 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
• 230000000451 tissue damage Effects 0.000 claims 1
• 231100000827 tissue damage Toxicity 0.000 claims 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 description 29